Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/30292
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Burrows, Lori | - |
dc.contributor.author | Coles, Victoria | - |
dc.date.accessioned | 2024-10-01T19:28:04Z | - |
dc.date.available | 2024-10-01T19:28:04Z | - |
dc.date.issued | 2024 | - |
dc.identifier.uri | http://hdl.handle.net/11375/30292 | - |
dc.description.abstract | As antimicrobial resistance proliferates, standard treatments for bacterial infections are rendered ineffective. There is therefore a need to both prevent infections and develop new treatment options. This need is especially urgent for priority pathogens like methicillin-resistant strains of Staphylococcus aureus (MRSA). Developing new antibiotics is difficult for a variety of reasons, including virulence traits like the formation of biofilms, surface-associated bacterial communities that are less susceptible to antibiotics. Here we used biofilms to our advantage, since their formation is stimulated when bacteria are exposed to sub-lethal concentrations of antibiotics, allowing us to screen for compounds with antimicrobial activity that would be missed with traditional methods. Using this approach, we identified the anti-inflammatory compound BAY 11-7082 as an antibiotic. We showed that it inhibits growth of priority pathogens including MRSA and provide evidence to suggest it has a novel (and potentially multifaceted) mechanism. We also found it re-sensitizes MRSA to inexpensive and readily available β-lactam antibiotics like penicillin G. This finding was of particular interest since using antibiotic adjuvants in combination with existing antibiotics provides a promising and complementary strategy to antibiotic discovery. We showed that wall teichoic acids, polymer chains anchored to the S. aureus cell wall, were required for sensitization to occur; however, unlike existing adjuvants, BAY 11-7082 did not appear to impact cell morphology or division, suggesting it instead targets a factor of β-lactam resistance that may be less well understood. Lastly, we examined the impact of common surgical antiseptics on bacterial growth and biofilm formation, with a goal of preventing infections following joint replacement. We found these solutions to be effective; however, it is important to define the concentrations at which they inhibit microbial growth in vivo, since sub-lethal concentrations stimulate biofilm formation. Taken together, the findings in this thesis bolster our understanding of how to reduce and treat resistant infections. | en_US |
dc.language.iso | en | en_US |
dc.title | Using Biofilms to Identify Novel Antibiotics and Assess Infection Prevention Methods | en_US |
dc.title.alternative | ANTIBIOTIC DISCOVERY AND INFECTION TREATMENT AND PREVENTION | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | Biochemistry | en_US |
dc.description.degreetype | Thesis | en_US |
dc.description.degree | Doctor of Philosophy (PhD) | en_US |
dc.description.layabstract | Antibiotics are pivotal to the success of modern medicine, but are becoming increasingly less effective because of antibiotic resistance. Resistance occurs when bacteria evolve ways of surviving exposure to antibiotics, and the overuse and misuse of antibiotics contributes to the spread of resistance through bacterial populations. This makes antibiotics currently used in the clinic less effective. Resistant strains of Staphylococcus aureus represent a major public health concern and are one of the most common causes of infections following joint replacement and medical device implantation. There are multiple approaches to prevent the rise of resistant S. aureus infections. In this thesis I: (1) identify a new antibiotic with activity against resistant species; (2) explore this antibiotic’s ability to re-sensitize resistant species to existing antibiotics; and (3) validate the activity of antiseptics used to prevent biofilm infections during surgery. Used together, these approaches help limit the spread of resistant infections. | en_US |
Appears in Collections: | Open Access Dissertations and Theses |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Coles_Victoria_E_2024Aug_PhD.pdf | 7.52 MB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.